title: The role of external radiotherapy in patients treated with permanent prostate brachytherapy.
abstract: To examine the difference in Prostate Specific Antigen (PSA)-Relapse Free Survival (RFS) in patients (pts) with prostate cancer treated with permanent prostate brachytherapy (PPB) alone (monotherapy) or combined modality PPB and external radiotherapy (CMT) by a matched pair analysis. There were 1476 pts who were treated loosely based on the American Brachytherapy Society criteria for monotherapy or CMT. PSA-RFS was based upon the Kattan modification of the ASTRO consensus panel definition. A computer generated matching process was undertaken to produce two equally weighted pairs of patients divided by treatment methodology and Kaplan-Meier PSA-RFS curves were generated and compared by chi(2) testing. All pts were treated between 1992 and 2000 with a 6-y PSA-RFS of 81.9%. The median follow-up was 34.7 months. Patients treated with CMT presented with higher pre-treatment PSA values, Gleason sum score, clinical stage, risk classification, and were more likely to be treated with neoadjuvant hormones. A matched-pair analysis with 314 pts in each group was created stratified by the addition of neoadjuvant hormones, Gleason score sum and the pretreatment PSA value. Actuarial 5-y PSA-RFS was 77.0% for the monotherapy group and 81.1% for the combined therapy group (P=0.54).chi(2) testing by pretreatment PSA value, Gleason score sum, risk stratification, isotope and the addition of neoadjuvant hormones failed to identify any group with a significant difference in 5-y PSA-RFS. In conclusion, this retrospective study presents a large cohort of patients treated with PPB that failed to identify a significant advantage for the addition of combined therapy. A matched pair analysis performed also failed to identify any significant difference based on treatment modality.
authors.affiliation: Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA. Pottersl@mskcc.org
authors.forename: L
authors.initials: L
authors.lastname: Potters
authors.forename: P
authors.initials: P
authors.lastname: Fearn
authors.forename: M
authors.initials: M
authors.lastname: Kattan
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000473:pathology / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001918:Brachytherapy; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen